CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

被引：1
|
作者：
Xuan, Jiachen [1 ,2 ]
Pearson, Richard B. [1 ,2 ,3 ,4 ]
Sanij, Elaine [1 ,2 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[3] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
[4] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia
[5] Univ Melbourne, Dept Clin Pathol, Parkville, Vic, Australia
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 06期
基金：
英国医学研究理事会;
关键词：
Ovarian cancer; PARPI; drug resistance; CX-5461;
D O I：
10.1080/23723556.2020.1805256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
    Makhale, Ashwini
    Nanayakkara, Devathri
    Raninga, Prahlad
    Khanna, Kum Kum
    Kalimutho, Murugan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [22] PARP inhibitor nano-therapy in ovarian cancer models
    Tangutoori, Shifalika
    Baldwin, Paige
    Medina, Jamie
    Ohman, Anders
    Dinulescu, Daniela
    Sridhar, Srinivas
    CLINICAL CANCER RESEARCH, 2015, 21
  • [23] Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
    Qin Tang
    Xin Wang
    Haixia Wang
    Lin Zhong
    Dongling Zou
    Cancer Biology & Medicine, 2023, 20 (12) : 915 - 921
  • [24] Establishment of PARP inhibitor-induced resistant patient-derived ovarian cancer xenograft models
    Hua, Li
    Li, Shuang
    Nie, Chenpan
    Chen, Xiaobo
    Sheng, Guo
    Bourre, Ludovic
    Wang, Jingjing
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
    Tang, Qin
    Wang, Xin
    Wang, Haixia
    Zhong, Lin
    Zou, Dongling
    CANCER BIOLOGY & MEDICINE, 2023, 20 (12)
  • [26] AKT1 prevents aberrant R-loops accumulation via regulating DHX9 and suppresses transcription-replication collision in PARP inhibitor-resistant ovarian cancer
    Huang, Tzu-Ting
    Chiang, Chih-Yuan
    Nair, Jayakumar R.
    Shih, Chi-Ting
    Wilson, Kelli
    Cheng, Ken Chih-Chien
    Lee, Jung-Min
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
    Kim, Hyoung
    Xu, Haineng
    George, Erin
    Hallberg, Dorothy
    Kumar, Sushil
    Jagannathan, Veena
    Medvedev, Sergey
    Kinose, Yasuto
    Devins, Kyle
    Verma, Priyanka
    Ly, Kevin
    Wang, Yifan
    Greenberg, Roger A.
    Schwartz, Lauren
    Johnson, Neil
    Scharpf, Robert B.
    Mills, Gordon B.
    Zhang, Rugang
    Velculescu, Victor E.
    Brown, Eric J.
    Simpkins, Fiona
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [28] Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
    Hyoung Kim
    Haineng Xu
    Erin George
    Dorothy Hallberg
    Sushil Kumar
    Veena Jagannathan
    Sergey Medvedev
    Yasuto Kinose
    Kyle Devins
    Priyanka Verma
    Kevin Ly
    Yifan Wang
    Roger A. Greenberg
    Lauren Schwartz
    Neil Johnson
    Robert B. Scharpf
    Gordon B. Mills
    Rugang Zhang
    Victor E. Velculescu
    Eric J. Brown
    Fiona Simpkins
    Nature Communications, 11
  • [29] The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
    Shunfei Yan
    Jiachen Xuan
    Natalie Brajanovski
    Madeleine R. C. Tancock
    Piyush B. Madhamshettiwar
    Kaylene J. Simpson
    Sarah Ellis
    Jian Kang
    Carleen Cullinane
    Karen E. Sheppard
    Katherine M. Hannan
    Ross D. Hannan
    Elaine Sanij
    Richard B. Pearson
    Keefe T. Chan
    British Journal of Cancer, 2021, 124 : 616 - 627
  • [30] Comparative whole genome analyses of aromatase inhibitor-resistant breast cancer models
    Hoppe, R.
    Kandabarau, S.
    Fan, P.
    Jordan, V. C.
    Brauch, H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S51 - S51
12345